Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel, NIDA ARRA Go Applications on Genetics, Harmonizing Phenotypes and Envirotypes, Epigenetics and Pharmacogenomics.                    

*Date:*                         July 16, 2009.                    

*Time:*                         8 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Washington Plaza Hotel, 10 Thomas Circle, NW., Washington, DC 20005.                    

*Contact Person:*                         Gerald L. McLaughlin, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., Bethesda, MD 20892-8401, 301-402-6626,                         *gm145a@nih.gov.*

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel, ARRA GO Criminal Justice Grant Application Review.                    

*Date:*                         July 23, 2009.                    

*Time:*                         8 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015.                    

*Contact Person:*                         Gerald L. McLaughlin, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., Bethesda, MD 20892-8401, 301-402-6626,                         *gm145a@nih.gov.*

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel, ARRA GO CTN-Based Grant Application Review.                    

*Date:*                         July 27, 2009.                    

*Time:*                         9 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852.                     

*Contact Person:*                         Mark R. Green, PhD, Deputy Director, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-8401, (301) 435-1431,                         *mgreen1@nida.nih.gov.*

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel, ARRA GO Small Molecule and Vaccine Medications.                    

*Date:*                         July 28, 2009.                    

*Time:*                         8 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Sofitel Washington DC, Lafayette Hotel, 806 15th Street, NW., Washington, DC 20005.                    

*Contact Person:*                         Jose F Ruiz, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, 6101 Executive Blvd., Rm. 213, MSC 8401, Bethesda, MD 20892, 301-451-3086,                         *ruizjf@nida.nih.gov.*

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel, NIDA Conference Grant Application Review.                    

*Date:*                         July 30, 2009.                    

*Time:*                         10 a.m. to 1 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).                    

*Contact Person:*                         Mark R. Green, PhD, Deputy Director, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-8401, (301)435-1431,                         *mgreen1@nida.nih.gov.*

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel, ARRA Grand Opportunities: Prevention Infrastructure.                    

*Date:*                         August 4, 2009.                    

*Time:*                         9 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         The Dupont Hotel, 1500 New Hampshire Avenue, NW., Washington, DC 20036.                    

*Contact Person:*                         Nadine Rogers, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-8401, 301-402-2105,                         *rogersn2@nida.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 91279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: July 1, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9-16067 Filed 7-9-09; 8:45 am]

BILLING CODE 4140-01-M